Investigational drug · Phase 2
BAY 3670549
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Atrial Fibrillation.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "BAY 3670549"
First trial start
2026
Sep 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BAY 3670549", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atrial Fibrillation
Approved drugs for the same conditions: Atrial fibrillation · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "BAY 3670549" as an intervention, largest first.
- A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial FibrillationPivotal-lookingRecruiting
BayerBayer (BAYRY)
NCT07625215 · 360 participants (planned) · Start Sep 1, 2026 · Primary completion May 16, 2030
Drug: BAY 3670549 · For: Atrial Fibrillation
Sites: San Francisco, California; Aurora, Colorado; Boston, Massachusetts · 30 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Atrial Fibrillation
- MilvexianJNJ-70033093, BMS-986177Phase 33 trials
Johnson & Johnson (Janssen) · Ischemic Stroke; Ischemic Attack, Transient, Atrial Fibrillation, Acute Coronary Syndrome
- HBI-3000sulcardine sulfatePhase 21 trial
HUYABIO International, LLC. · Atrial Fibrillation
- PKN605Phase 21 trial
Novartis · Atrial Fibrillation
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bayer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.